It was demonstrated that in RR-MS patients, a hypermethylated E-cadherin (CDH1) profile can increase blood–brain barrier permeability, allowing lymphocyte infiltration into the brain and, ultimately, the progression of the disease [39]. Here, CDH1 is linked to myeloid sarcoma.